AstraZeneca Pharma India Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report '.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India has filed its annual Business Responsibility and Sustainability Report (BRSR) for FY 2024-25, as required by SEBI regulations. The company reported a total turnover of ₹17,162.9 million, with exports contributing ₹1,096.9 million (6.4%) to Nepal. It has 747 permanent employees (23% female) and 55 permanent workers across 1 manufacturing plant and 2 offices in India. The board has 75% female representation. No regulatory fines, penalties, or fatalities were recorded during the year, though 12 recordable work-related injuries occurred among employees. Employee attrition rose sharply to 24.19% (from 12% in FY 2023-24) due to a Mutual Separation Programme. The company has set targets to achieve Zero Carbon emissions by 2025 and Carbon Negative by 2030, but the BRSR has not been externally assured.
This is a routine annual compliance disclosure with no material negative news for shareholders. The sharp rise in employee attrition and lack of third-party assurance on the BRSR are minor points to note, but overall operations appear stable with no regulatory actions. No immediate impact on stock price is expected from this filing.